Impact of Interleukin-6 in Hematological Malignancies
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Almost 3 decades have passed since the discovery and cloning of IL-6, and a tremendous amount of work has contributed to the current knowledge of the biological functions of this cytokine, its receptor, and the signaling pathways that are activated. The understanding of the role of IL-6 in human disease has led to the development of novel therapeutic strategies that block the biological functions of IL-6. In clinical studies, IL-6 and IL-6 receptor antibodies have proven efficacy in rheumatoid arthritis, systemic juvenile idiopathic arthritis, and Castleman's disease, conditions that are known to be driven by IL-6. The focus of this overview is the role of IL-6 in the pathophysiology of hematological malignancies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Principles of interleukin (IL)-6-type cytokine signalling and its regulation
HEINRICH, P. C., BEHRMANN, I., HAAN, S., HERMANNS, H. M., MÜLLER-NEWEN, G., & SCHAPER, F. (2003) · Biochemical Journal · doi:10.1042/bj20030407 · Cited by 3,272 · cited 1×
“Mice deficient in Raf/mitogen-activated protein kinase (MAPK) cascade, and the phosphatidylinositol-3 kinase (PI3K)/protein kinase B (AKT) pathway [6].”
BackgroundThe pro- and anti-inflammatory properties of the cytokine interleukin-6
Scheller, J., Chalaris, A., Schmidt-Arras, D., & Rose-John, S. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.01.034 · Cited by 3,212 · cited 1×
“Therefore, during IL-6-mediated responses, the contribution of classic signaling through the membrane IL-6R versus transsignaling involving IL-6/sIL-6R depends on the physiological context and could have therapeutic implications [8, 9]. tological tumors, acting in an autocrine or paracrine manner.”
BackgroundImpaired immune and acute-phase responses in interleukin-6-deficient mice
Kopf, M., Baumann, H., Freer, G., Freudenberg, M., Lamers, M., Kishimoto, T., Zinkernagel, R., Bluethmann, H., & Köhler, G. (1994) · Nature · doi:10.1038/368339a0 · Cited by 1,768
Catlett-Falcone, R., Landowski, T. H., Oshiro, M. M., Turkson, J., Levitzki, A., Savino, R., Ciliberto, G., Moscinski, L., Fernández-Luna, J. L., Nuñez, G., et al. (1999) · Immunity · doi:10.1016/s1074-7613(00)80011-4 · Cited by 1,638
Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas
Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwato, K., Asaoku, H., Tang, B., Tanabe, O., Tanaka, H., et al. (1988) · Nature · doi:10.1038/332083a0 · Cited by 1,633 · cited 1×
“Some myeloma cells can produce their own IL-6 [32], but BM stromal cells are the main source, establishing a strong paracrine growth stimulation for the malignant plasma cells [33].”
BackgroundPathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman’s disease
Yoshizaki, K., Matsuda, T., Nishimoto, N., Kuritani, T., Taeho, L., Aozasa, K., Nakahata, T., Kawai, H., Tagoh, H., & Komori, T. (1989) · Blood · doi:10.1182/blood.v74.4.1360.1360 · Cited by 928 · cited 1×
“Constitutive production of IL-6 by B cells in the germinal centers of the affected lymph nodes is associated with increased IL-6 serum levels [23].”
BackgroundIL-6: From its discovery to clinical applications
Kishimoto, T. (2010) · International Immunology · doi:10.1093/intimm/dxq030 · Cited by 846 · cited 3×
“Tocilizumab is a humanized anti-IL-6R antibody which binds to the IL-6 binding site of human IL-6R and competitively inhibits IL-6 signaling [1].”
BackgroundInfluentialHumanized anti–interleukin-6 receptor antibody treatment of multicentric Castleman disease
Nishimoto, N., Kanakura, Y., Aozasa, K., Johkoh, T., Nakamura, M., Nakano, S., Nakano, N., Ikeda, Y., Sasaki, T., Nishioka, K., et al. (2005) · Blood · doi:10.1182/blood-2004-12-4602 · Cited by 754
Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma
Hideshima, T., Nakamura, N., Chauhan, D., & Anderson, K. C. (2001) · Oncogene · doi:10.1038/sj.onc.1204833 · Cited by 478 · cited 1×
“IL-6 also induces the Ras/Raf/MAPK and the PI3K/AKT pathway in MM cells [37].”
BackgroundInterleukin‐6 and its receptor in cancer: Implications for Translational Therapeutics
Hong, D. S., Angelo, L. S., & Kurzrock, R. (2007) · Cancer · doi:10.1002/cncr.22999 · Cited by 370
Cited by
Neuroprotective effects of physical activity on the brain: a closer look at trophic factor signaling
Phillips, C., Baktir, M. A., Srivatsan, M., & Salehi, A. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00170 · Cited by 330
“…underlying the effects of exercise on cognition might be related to its effects on inflammatory factors IL-6, IL-8, CXCL12, CRP, and TNF. 1) IL-6 is a pro-inflammatory cytokine released in the periphery by T-cells, macrophages, fibroblasts, endothelial cells, and osteoblasts (Burger, 2013).”
BackgroundPhillips, C. (2017) · Neural Plasticity · doi:10.1155/2017/3589271 · Cited by 327
Binder, S., Luciano, M., & Horejs-Hoeck, J. (2018) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2018.08.004 · Cited by 190
Musolino, C., Allegra, A., Innao, V., Allegra, A. G., Pioggia, G., & Gangemi, S. (2017) · Mediators of Inflammation · doi:10.1155/2017/1852517 · Cited by 168
Lin, W. W., Yi, Z., Stunz, L. L., Maine, C. J., Sherman, L. A., & Bishop, G. A. (2015) · Science Signaling · doi:10.1126/scisignal.aaa5157 · Cited by 50
“Dysregulated IL-6R signaling is observed in B cell malignancies and solid tumors (23, 24).”
Background
Metadata
- Authors
- Burger, R.
- Venue
- Transfusion Medicine and Hemotherapy
- Publisher
- S. Karger AG
- Published
- 2013
- Volume
- 40
- Issue
- 5
- Pages
- 336-343
- ISSN
- 1660-3796 (ISSN-L)
- 1660-3818
- OpenAlex
- W2058788010
- Cited by
- 116
- References
- 12
- FWCI
- 4.74
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Impact of Interleukin-6 in Hematological Malignancies. https://app.cochat.ai/papers/10.1159/000354194
- The paper
- Burger, R. (2013). Impact of Interleukin-6 in Hematological Malignancies. Transfusion Medicine and Hemotherapy. https://doi.org/10.1159/000354194
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.